Heart failure (HF) refers to a clinical syndrome with a worldwide increasing prevalence characterized by high morbidity and mortality in developed and developing countries. HF is a major public health concern causing tremendous economic burden. More than 40% of HF patients die within 1 year of their first hospitalization and 1 in every 3 to 4 patients is readmitted within 1 year, emphasizing the enormous health care cost associated with HF. Recently, despite major improvement in the management of HF, the morbidity of HF is still on the rise, partially due to ageing populations and the increased survival of patients after myocardial infarction.
In ageing populations, early phenotyping and stratification of individuals with left ventricular diastolic and systolic dysfunction with unprecedented accuracy, when prevention still is possible, is of paramount importance. Valid novel biomarkers might potentially provide the necessary kind of phenotyping and stratification allowing “personalized medicine” (e.g., timely intervention).
HF can clinically present with predominantly left ventricular systolic or diastolic dysfunction, or both. Recent HF guidelines place special emphasis on the detection of subclinical left ventricular dysfunction and the timely identification of risk factors for progression to symptomatic HF. However, easily applicable screening techniques for timely detection of asymptomatic stages of left ventricular dysfunction are still lacking. The current Research Topic aims to find novel risk factors of HF as diagnostic and prognostic cues allowing the early detection of HF.
Suggested sub-themes include:
1) Novel circulating or urinary biomarker in HF.
2) Novel genetic biomarker in HF.
3) Multidimensional “omics” biomarker in HF.
4) Non-invasively measured biomarker signatures in HF.
5) Novel clinical parameters for risk prediction in HF.
6) Novel risk factors for (e.g., cardio-renal, cardio-liver, psychological) complications in HF.
Heart failure (HF) refers to a clinical syndrome with a worldwide increasing prevalence characterized by high morbidity and mortality in developed and developing countries. HF is a major public health concern causing tremendous economic burden. More than 40% of HF patients die within 1 year of their first hospitalization and 1 in every 3 to 4 patients is readmitted within 1 year, emphasizing the enormous health care cost associated with HF. Recently, despite major improvement in the management of HF, the morbidity of HF is still on the rise, partially due to ageing populations and the increased survival of patients after myocardial infarction.
In ageing populations, early phenotyping and stratification of individuals with left ventricular diastolic and systolic dysfunction with unprecedented accuracy, when prevention still is possible, is of paramount importance. Valid novel biomarkers might potentially provide the necessary kind of phenotyping and stratification allowing “personalized medicine” (e.g., timely intervention).
HF can clinically present with predominantly left ventricular systolic or diastolic dysfunction, or both. Recent HF guidelines place special emphasis on the detection of subclinical left ventricular dysfunction and the timely identification of risk factors for progression to symptomatic HF. However, easily applicable screening techniques for timely detection of asymptomatic stages of left ventricular dysfunction are still lacking. The current Research Topic aims to find novel risk factors of HF as diagnostic and prognostic cues allowing the early detection of HF.
Suggested sub-themes include:
1) Novel circulating or urinary biomarker in HF.
2) Novel genetic biomarker in HF.
3) Multidimensional “omics” biomarker in HF.
4) Non-invasively measured biomarker signatures in HF.
5) Novel clinical parameters for risk prediction in HF.
6) Novel risk factors for (e.g., cardio-renal, cardio-liver, psychological) complications in HF.
